The DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index.
Arterial Hypertension Induced by Erythropoietin and Erythropoiesis-Stimulating Agents (ESA)
Abstract
This review summarizes the evidence for a hypertensinogenic effect of Erythropoietin (Epo) in normal human subjects and predialysis, hemodialysis, and continuous ambulatory peritoneal dialysis (CAPD) patients. The possible mechanisms of Epo-induced hypertension are examined with in vivo animal and in vitro data, as well as pathophysiological human studies in both normal subjects and CKD patients. The evidence for a hypertensinogenic effect of erythropoiesis-stimulating agents (ESAs) in normal subjects, predialysis CKD, hemodialysis, and CAPD patients is compelling. Epo increases BP directly and notably independently of its erythropoietic effect and its effect on blood rheology. The potential for the development of future agents that might act as specific stimulators of erythropoiesis, devoid of direct hemodynamic side effects is underscored.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NSAIDs can antagonize the effects of RAAS-inhibitors and beta blockers”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [41]
In the citing paper
“No increase in blood pressure with aspirin”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [41]
In the citing paper
“3/1 mm Hg increase with nonselective NSAIDs”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [41]
In the citing paper
“No difference or an increase of up to 3/1 mm Hg with celecoxib”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [41]
In the citing paper
“Increased odds ratio of 3.19 of hypertension with tricyclic antidepressant”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [41]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762 · cited 9×
“Epo treatment showed a trend to an increased risk for hypertensive AEs by 26% as compared with no Epo/placebo, but the effect was not statistically significant.”
BackgroundInfluentialNormalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K.-U., Macdougall, I. C., Tsakiris, D., Burger, H.-U., & Scherhag, A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062276 · Cited by 2,104 · cited 10×
“Epo treatment showed a trend to an increased risk for hypertensive AEs by 26% as compared with no Epo/placebo, but the effect was not statistically significant.”
BackgroundInfluentialEschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795 · cited 1×
“magnitude of the Epo-induced increase in BP (32).”
BackgroundStroke risk profile: adjustment for antihypertensive medication. The Framingham Study.
D'Agostino, R. B., Wolf, P. A., Belanger, A. J., & Kannel, W. B. (1994) · Stroke · doi:10.1161/01.str.25.1.40 · Cited by 712
Phrommintikul, A., Haas, S. J., Elsik, M., & Krum, H. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60194-9 · Cited by 638 · cited 1×
“Recently, another meta-analysis (24) reported the hypertension AEs in controlled trials that targeted high versus low blood Hb values and included trials previously included in a metaanalysis (21).”
BackgroundSecondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes
Szczech, L. A., Barnhart, H. X., Inrig, J. K., Reddan, D. N., Sapp, S., Califf, R. M., Patel, U. D., & Singh, A. K. (2008) · Kidney International · doi:10.1038/ki.2008.295 · Cited by 526
Parfrey, P. S., Foley, R. N., Wittreich, B. H., Sullivan, D. J., Zagari, M. J., & Frei, D. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004121039 · Cited by 373 · cited 2×
“One Hb target-controlled trial (41) did not find”
BackgroundHealth centres of today; Finsbury, Peckham.
STEWART, A. B., & Williamson, G. S. (1946) · PubMed · Cited by 256
Revicki, D. A., Brown, R. E., Feeny, D. H., Henry, D., Teehan, B. P., Rudnick, M. R., & Benz, R. L. (1995) · American Journal of Kidney Diseases · doi:10.1016/0272-6386(95)90122-1 · Cited by 254 · cited 1×
“96) Revicki 1995 (91) Predialysis 4/40 11/43 16.”
Casati, S., Passerini, P., Campise, M. R., Graziani, G., Cesana, B., Perisic, M., & Ponticelli, C. (1987) · BMJ · doi:10.1136/bmj.295.6605.1017 · Cited by 242
Cited by
2020 International Society of Hypertension Global Hypertension Practice Guidelines
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15026 · Cited by 4,132
2020 International Society of Hypertension global hypertension practice guidelines
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002453 · Cited by 1,283
Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia
Kuhn, V., Diederich, L., Keller, T. C. S., Kramer, C. M., Lückstädt, W., Panknin, C., Suvorava, T., Isakson, B. E., Kelm, M., & Cortese-Krott, M. M. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6954 · Cited by 469
“Indeed, it was shown that EPO administration to normovolemic anemic patients increased systemic vascular resistance and arterial blood pressure and decreased cardiac output due to diminished heart rate and venous return (103, 194).”
Provenzano, R., Besarab, A., Sun, C. H., Diamond, S. A., Durham, J. H., Cangiano, J. L., Aiello, J. R., Novak, J. E., Lee, T., Leong, R., et al. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06890615 · Cited by 290
“6% of treated patients) was below what has been reported for similar patient populations treated with ESAs (16%–32%) (35,36) and comparable with placebo rates seen in other similar studies in this patient population (37).”
Sarafidis, P. A., Persu, A., Agarwal, R., Burnier, M., de Leeuw, P., Ferro, C. J., Halimi, J.-M., Heine, G. H., Jadoul, M., Jarraya, F., et al. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw433 · Cited by 229
Flamme, I., Oehme, F., Ellinghaus, P., Jeske, M., Keldenich, J., & Thuss, U. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111838 · Cited by 170
“This could contribute to the increased blood pressure observed in patients with CKD treated with rhEPO because EPO has been found to directly induce endothelial dysfunction in resistance arteries in patients with CKD [4–6].”
BackgroundHypertension in chronic kidney disease: What lies behind the scene
Ameer, O. Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.949260 · Cited by 200
“Erythropoietin, implicated in the treatment of anemia associated with CKD, is overlooked as a causative agent for BP elevation (Krapf and Hulter, 2009; Agarwal, 2018).”
BackgroundErythropoietin: A Hormone with Multiple Functions
Lombardero, M., Kovács, K., & Scheithauer, B. W. (2011) · Pathobiology · doi:10.1159/000322975 · Cited by 143
“This is, in part, due to its hypertensiogenic effect [”
BackgroundWeltert, L. P., Rondinelli, B., Bello, R. A., Falco, M., Bellisario, A., Maselli, D., Turani, F., Paulis, R. D., & Pierelli, L. (2015) · Transfusion · doi:10.1111/trf.13027 · Cited by 116
“00 CPB time (min) 60 (28-160) 66 (32-151) 0.”
InfluentialVera‐Aviles, M., Vantana, E., Kardinasari, E., Koh, N. L., & Latunde-Dada, G. O. (2018) · Pharmaceuticals · doi:10.3390/ph11040111 · Cited by 126
“Recombinant HuEPO treatment is furthermore associated with increased blood pressure and blood clotting [41,42].”
BackgroundMeadowcroft, A. M., Čižman, B., Holdstock, L., Biswas, N., Johnson, B. M., Jones, D., Nossuli, A. K. K., Lepore, J. J., Aarup, M., & Cobitz, A. R. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy014 · Cited by 113
“Consistent with the known AEs of rhEPO [29], the control group had an increase in systolic BP at Week 24.”
BackgroundHypertension, left ventricular hypertrophy and chronic kidney disease
Taddei, S., Nami, R., Bruno, R. M., Quatrini, I., & Nuti, R. (2010) · Heart Failure Reviews · doi:10.1007/s10741-010-9197-z · Cited by 112
“Finally, erythropoietin, a cornerstone in treatment of anemia associated with CKD, can frequently cause hypertension [22].”
BackgroundEffects of Molidustat in the Treatment of Anemia in CKD
Macdougall, I. C., Akizawa, T., Berns, J. S., Bernhardt, T., & Krueger, T. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02510218 · Cited by 111
Babiker, H. M., McBride, A., Newton, M., Boehmer, L., Drucker, A., Gowan, M., Cassagnol, M., Camenisch, T. D., Anwer, F., & Hollands, J. M. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.014 · Cited by 111
Epidemiology of Interdialytic Ambulatory Hypertension and the Role of Volume Excess
Agarwal, R. (2011) · American Journal of Nephrology · doi:10.1159/000331067 · Cited by 107
“In this study, we found that epoetin use, fewer years on dialysis, and a lower BMI were independently associated with prevalent hypertension. The association of epoetin use with hypertension is now well recognized [”
BackgroundRossignol, P., Cridlig, J., Lehert, P., Kessler, M., & Zannad, F. M. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.190397 · Cited by 97
Hypertension in patients on dialysis: diagnosis, mechanisms, and management
Bucharles, S. G. E., Wallbach, K. K. S., de Moraes, T. P., & Pecoits‐Filho, R. (2018) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2018-0155 · Cited by 89
Effects of recombinant human erythropoietin in normal humans
Lundby, C., & Olsen, N. V. (2010) · The Journal of Physiology · doi:10.1113/jphysiol.2010.195917 · Cited by 87
“The reduction in plasma volume induced by EPO may be caused by natriuresis secondary to the hyporeninaemic hypoaldosteronism (Lundby et al 2007; Krapf & Hulter 2009).”
BackgroundSystemic Hypertension at High Altitude
Narvaez-Guerra, O. D., Herrera-Enriquez, K. B., Medina‐Lezama, J., & Chirinos, J. A. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11140 · Cited by 88
“subjects, and this seems to be independent of its effects on red blood cell volume.(81) These effects could involve a dose-”
BackgroundAkizawa, T., Iwasaki, M., Otsuka, T., Reusch, M., & Misumi, T. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00943-4 · Cited by 87
Hypertension in Pediatric Long-term Hemodialysis Patients in the United States
Chavers, B. M., Solid, C. A., Daniels, F., Chen, S., Collins, A. J., Frankenfield, D. L., & Herzog, C. A. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01440209 · Cited by 91
Hypertension in dialysis patients
Sarafidis, P. A., Persu, A., Agarwal, R., Burnier, M., de Leeuw, P. W., Ferro, C. J., Halimi, J., Heine, G. H., Jadoul, M. Y., Jarraya, F., et al. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001283 · Cited by 89
Drug-related hypertension and resistance to antihypertensive treatment: a call for action
Rossi, G. P., Seccia, T. M., Maniero, C., & Pessina, A. C. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834c465d · Cited by 74
Goodkin, D. A., Fuller, D. S., Robinson, B. M., Combe, C., Fluck, R., Mendelssohn, D. C., Akizawa, T., Pisoni, R. L., & Port, F. K. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010020173 · Cited by 67
Yang, C., Zhao, T., Lin, M., Zhao, Z., Hu, L., Jia, Y., Xue, Y., Xu, M., Tang, Q., Yang, B., et al. (2013) · Experimental Biology and Medicine · doi:10.1258/ebm.2012.012185 · Cited by 67
Intolerability of cobalt salt as erythropoietic agent
Ebert, B., & JELKMANN, W. E. B. (2013) · Drug Testing and Analysis · doi:10.1002/dta.1528 · Cited by 66
“This is in harmony with present knowledge that the treatment with rhEpo can be associated with an increase in blood pressure, although the mechanisms of this increase are not fully understood.([54,55])”
ResultRenal anemia: from incurable to curable
Sato, Y., & Yanagita, M. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00233.2013 · Cited by 64
“However, adverse effects of rhEPO, such as hypertension and thrombotic complications, have also been reported (60, 128).”
BackgroundBeverborg, N. G., Verweij, N., Klip, I. T., van der Wal, H. H., Voors, A. A., van Veldhuisen, D. J., Gansevoort, R. T., Bakker, S. J. L., van der Harst, P., & van der Meer, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125215 · Cited by 60
Mechanisms and mediators of hypertension induced by erythropoietin and related molecules
Agarwal, R. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx324 · Cited by 60
“However, EPO-induced hypertension is very common among those with CKD, including those on dialysis [6].”
BackgroundAkizawa, T., Macdougall, I. C., Berns, J. S., Bernhardt, T., Staedtler, G., Taguchi, M., Iekushi, K., & Krueger, T. (2019) · American Journal of Nephrology · doi:10.1159/000499111 · Cited by 58
The growing problem of intradialytic hypertension
Locatelli, F., Cavalli, A., & Tucci, B. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.200 · Cited by 46
“An increase in hematocrit and blood viscosity and an elevation of ET-1 concentrations and increased peripheral vascular resistance might explain this finding”
BackgroundTargeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis
Rainville, N., Jachimowicz, E., & Wojchowski, D. M. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1090975 · Cited by 45
“One major impetus for pursuing erythropoiesis-stimulating agents (ESAs) beyond rhEPO and biosimilars therefore relates to side effects, with hypertension frequently experienced among CKD patients [24-26].”
BackgroundCardiovascular Effects of Erythropoietin
Santhanam, A. V. R., d’Uscio, L. V., & Katušić, Z. S. (2010) · Advances in pharmacology · doi:10.1016/b978-0-12-385061-4.00009-x · Cited by 44
“Similar doses of EPO (200 U/mL) released ET-1 and increased constrictor prostanoids over dilator prostanoids in vitro in endothelial cells (Bode-Boger et al., 1996; Krapf & Hulter, 2009) and these observations may help to explain EPO-induced hypertension observed in animals and in humans.”
Hypertension and hemodialysis: pathophysiology and outcomes in adult and pediatric populations
Buren, P. N. V., & Inrig, J. K. (2011) · Pediatric Nephrology · doi:10.1007/s00467-011-1775-3 · Cited by 44
“Further details on this topic are beyond the scope of this review, but may be found in a previous review on the subject [56].”
BackgroundRitchie, J. P., Rainone, F., Green, D., Alderson, H. V., Chiu, D. Y. Y., Middleton, R., O'Donoghue, D. J., & Kalra, P. A. (2013) · International Journal of Hypertension · doi:10.1155/2013/597906 · Cited by 44
Foy, M. C., Vaishnav, J., & Sperati, C. J. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.08.013 · Cited by 45
Role of the Kidneys in Resistant Hypertension
Khawaja, Z. Q., & Wilcox, C. S. (2011) · International Journal of Hypertension · doi:10.4061/2011/143471 · Cited by 46
“In another study of patients with resistant hypertension (mean baseline BP 163/91 mm Hg), spironolactone decreased BP to a similar degree as the ASCOT trial.”
ResultThiazide Diuretics in Chronic Kidney Disease
Sinha, A. D., & Agarwal, R. (2015) · Current Hypertension Reports · doi:10.1007/s11906-014-0525-x · Cited by 42
Böttcher, M., Lentini, S., Arens, E. R., Kaiser, A., van der Mey, D., Thuß, U., Kubitza, D., & Wensing, G. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13584 · Cited by 42
de Meent, D. G., den Adel, M., Noukens, J., Rijnders, S., Krebs‐Brown, A., Mateva, L., Alexiev, A., & Schaddelee, M. P. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0422-y · Cited by 41
“Current treatments are associated with side effects such as iron toxicity [7], anaphylactic reactions [8], cardiovascular risk [9], thromboembolic complications [10] and the risk for allosensitisation (due to blood transfusions), which is associated with the increased rejection of organ transplants [11].”
BackgroundHypertension in Small Animal Kidney Disease
Syme, H. M. (2011) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2010.11.002 · Cited by 53
Kolonko, A., Pinocy-Mańdok, J., Kocierz, M., Kujawa-Szewieczek, A., Chudek, J. T., Małyszko, J., Małyszko, J., Myśliwiec, M., & Więcek, A. (2009) · Transplantation Proceedings · doi:10.1016/j.transproceed.2009.07.090 · Cited by 38
Hu, Y., Zhao, Y., Li, P., Lu, H., Li, H., & Ge, J. (2023) · 中国科学通报:英文版 · doi:10.1016/j.scib.2023.07.032 · Cited by 41
Olsen, N. V., Aachmann‐Andersen, N. J., Oturai, P., Munch‐Andersen, T., Bornø, A., Hulston, C. J., Holstein‐Rathlou, N., Robach, P., & Lundby, C. (2010) · The Journal of Physiology · doi:10.1113/jphysiol.2010.194241 · Cited by 37
“It has been suggested that the reduction in plasma volume induced by rHuEPO may be caused by the hyporeninaemic hypoaldosteronism leading to natriuresis (Lundby et al. 2007; Krapf & Hulter, 2009).”
BackgroundAnand, L., Bihari, C., Kedarisetty, C. K., Rooge, S. B., Kumar, D., Shubham, S., Kumar, G., Sahney, A., Sharma, M. K., Maiwall, R., et al. (2018) · Liver International · doi:10.1111/liv.13923 · Cited by 37
Graves, A. R., Yates, P., Hofmann, A., Farmer, S. L., & Ferrari, P. (2014) · Nephrology · doi:10.1111/nep.12239 · Cited by 34
“It appears that erythropoietin increases blood pressure directly and independently of its erythropoietic effect and its effect on blood rheology.(35) Some authors reported a hypertensiongenic effect of ESA in haemodialysis patients of approximately 5–8 mmHg for systolic and 4–6 mmHg for diastolic blood pressure,(37) a…”
BackgroundArterial hypertension in patients under antineoplastic therapy: a systematic review
Katsi, V. K., Magkas, N., Georgiopoulos, G. A., Athanasiadi, E., Virdis, A., Masi, S., Kliridis, P., Hatziyianni, A., Tsioufis, C. P., & Tousoulis, D. M. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002006 · Cited by 35
Clinical use of erythropoietin in chronic kidney disease: outcomes and future prospects.
Provatopoulou, S., & Ziroyiannis, P. (2011) · Europe PMC (PubMed Central) · Cited by 34
High‐dose erythropoietin for tissue protection
Lund, A., Lundby, C., & Olsen, N. V. (2014) · European Journal of Clinical Investigation · doi:10.1111/eci.12357 · Cited by 31
Brar, S. K., Perveen, S., Chaudhry, M. R., Albabtain, S., Amreen, S., & Khan, S. (2021) · Cureus · doi:10.7759/cureus.12804 · Cited by 30
“[18] Erythropoietin’s effect on BP Review EPO causes hypertension in normal subjects, dialysis, and predialysis”
BackgroundInrig, J. K., Sapp, S. K., Barnhart, H. X., Patel, U. D., Reddan, D. N., Singh, A. K., Califf, R. M., & Szczech, L. A. M. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs123 · Cited by 30
“However, the hypothesis that increased BP among patients randomized to higher hemoglobin targets may lead to adverse outcomes has not been confirmed [6–9].”
BackgroundDev, A., Byrne, S. M., Verma, R. K., Ashton‐Rickardt, P. G., & Wojchowski, D. M. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20121762 · Cited by 29
Pathophysiology of Hypertension
Yamaguchi, I., & Flynn, J. T. (2009) · Springer eBooks · doi:10.1007/978-3-540-76341-3_61 · Cited by 30
Silverberg, D. S., Wexler, D., Palazzuoli, A., Iaina, A., & Schwartz, D. (2009) · Acta Haematologica · doi:10.1159/000243795 · Cited by 28
“Other Potential Problems with EPOHigh doses of ESA are potentially harmful for other reasons [ ,”
BackgroundGhanta, M., Kozicky, M., & Jim, B. (2014) · Cardiology in Review · doi:10.1097/crd.0000000000000044 · Cited by 32
“The reasons for this phenomenon are not exactly clear, though there is a role for ESA-induced vasoconstriction on renal resistance vessels, activation of the RAAS, upregulation of endothelin, and inhibition of NO.12,13 The treatment options of hypertension in ESRD patients are both pharmacologic and nonpharmacologic.”
BackgroundSingh, A. T., Waikar, S. S., & Causland, F. R. M. (2022) · Hypertension · doi:10.1161/hypertensionaha.121.18058 · Cited by 27
Prevalence and predictors of the sub-target Hb level in children on dialysis
van Stralen, K. J., Krischock, L., Schaefer, F., Verrina, E. E., Groothoff, J. W., Evans, J., Heaf, J. G., Ivanov, D. D., Kostic, M., Maringhini, S., et al. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs178 · Cited by 29
“ESA-induced hypertension might mainly occur in the initial correction phase [37] and could relate more to ESA dose than to Hb target.”
BackgroundChronic complications in hemodialysis: correlations with primary renal disease.
Checheriţă, I. A., Turcu, F. L., Dragomirescu, R. F. I., & Ciocâlteu, A. (2010) · PubMed · Cited by 27
Drug-induced hypertension: Know the problem to know how to deal with it
Masi, S., Uliana, M., Gesi, M., Taddei, S., & Virdis, A. (2019) · Vascular Pharmacology · doi:10.1016/j.vph.2019.02.002 · Cited by 32
Wang, B., Yin, Q., Han, Y., Wu, M., Li, Z., Tu, Y., Zhou, L., Wei, Q., Liu, H., Tang, R., et al. (2020) · Renal Failure · doi:10.1080/0886022x.2020.1811121 · Cited by 26
“affecting 10% patients with CKD, especially in hemodialysis patients [49]; Secondly, use of ESAs in CKD anemia treatment has raised safety concerns as the development or worsening of hypertension, greater risk for death, CV events, and stroke [10,11,13,43], Thirdly, there is a serious concern about the risk and conseq…”
BackgroundFibroblast heterogeneity and tertiary lymphoid tissues in the kidney
Arai, H., Sato, Y., & Yanagita, M. (2021) · Immunological Reviews · doi:10.1111/imr.12969 · Cited by 27
Erythropoietin and Resistant Hypertension in CKD
Boyle, S. M., & Berns, J. S. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.08.008 · Cited by 26
“Since the early years of erythropoiesis-stimulating agent (ESA) use, there has been a welldocumented relationship between recombinant erythropoietin use and blood pressure (BP) increase.(1,2) This relationship, although broadly recognized, is not well-elucidated at either a mechanistic or clinical level.”
BackgroundYamamoto, H., Taguchi, M., Matsuda, Y., Iekushi, K., Yamada, T., & Akizawa, T. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-026704 · Cited by 23
Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin?
Yousaf, F., & Spinowitz, B. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0629-6 · Cited by 25
Akizawa, T., Taguchi, M., Matsuda, Y., Iekushi, K., Yamada, T., & Yamamoto, H. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-026602 · Cited by 22
Roubille, F., Prunier, F., Barrère‐Lemaire, S., Leclercq, F., Piot, C. A., Kritikou, E. A., Rhéaume, É., Busseuil, D., & Tardif, J. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6461-1 · Cited by 23
Rasmussen, P., Kim, Y.-S., Krogh‐Madsen, R., Lundby, C., Olsen, N. V., Secher, N. H., & LIESHOUT, J. J. V. (2011) · The FASEB Journal · doi:10.1096/fj.11-193508 · Cited by 21
“In healthy volunteers, as in patients with chronic kidney disease, long-term administration of EPO provokes hypertension (7, 20), which might be due to the hematopoietic effect of EPA and, therefore, enhanced blood viscosity.”
BackgroundEffects of Roxadustat on the Anemia and Iron Metabolism of Patients Undergoing Peritoneal Dialysis
Hirai, K., Nonaka, H., Ueda, M., Morino, J., Kaneko, S., Minato, S., Mutsuyoshi, Y., Yanai, K., Ishii, H., Matsuyama, M., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.667117 · Cited by 21
“It has been reported that ESA dosedependently increases the incidence of hypertension in patients with CKD (18).”
BackgroundInfluentialPathogenesis of Drug-Resistant Hypertension
Townsend, R. R. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.08.004 · Cited by 21
Anemia in Chronic Kidney Disease: New Advances
Patel, T. V., & Singh, A. K. (2010) · Heart Failure Clinics · doi:10.1016/j.hfc.2010.02.001 · Cited by 21
“The potential mechanisms for ESA-induced hypertension have been discussed in great length elsewhere.(49) To avoid the hypertensive effects of ESA, Lee and colleagues reported the effects of EPO-binding protein (bp) and anti-EPO antibodies in Dawley-Sprague rats.”
BackgroundSingh, S., Dev, A., Verma, R. K., Pradeep, A., Sathyanarayana, P., Green, J. M., Narayanan, A., & Wojchowski, D. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038530 · Cited by 20
“In keeping with broadening concepts for EPO’s effects [1,2,3,4,5,6], functional sub-sets of EPO/EPOR- modulated targets included survival factors, cell cycle regulators, signal transduction factors, negative feedback factors and a select set of cytokines plus receptors (as defined in some detail below).”
Kowalczyk, M., Banach, M., Mikhailidis, D. P., & Rysz, J. (2011) · Medical Science Monitor · doi:10.12659/msm.882037 · Cited by 19
Chavan, A. B., Burke, L., Sawant, R., Navarro‐Gonzales, P., Vargo, D. L., & Paulson, S. K. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.927 · Cited by 21
Robles, N. R. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0378-y · Cited by 17
“A number of pathophysiological mechanisms have been postulated to explain the rise in blood pressure values observed after ESAs administration [9].”
BackgroundYang, C., Zhang, C., Jia, J., Wang, L., Zhang, W., Li, J., Xu, M., Rong, R., & Zhu, T. (2019) · Cell Death Discovery · doi:10.1038/s41420-019-0161-y · Cited by 17
ANAEMIA MANAGEMENT IN CARDIO RENAL DISEASE
Silverberg, D. S., Wexler, D., Iaina, A., & Schwartz, D. (2010) · Journal of Renal Care · doi:10.1111/j.1755-6686.2010.00164.x · Cited by 16
Midkine Regulation of the Renin-Angiotensin System
Kadomatsu, K. (2010) · Current Hypertension Reports · doi:10.1007/s11906-010-0092-8 · Cited by 16
Österreichischer Blutdruckkonsens 2019
Hypertensiologie, Ö. G. F., Weber, T., Atherosklerosegesellschaft, Ö., Gesellschaft, Ö. D., Angiologie, Ö. G. F. I., Nephrologie, Ö. G. F., Gesellschaft, Ö. K., Neurologie, Ö. G. F., Schlaganfall-Gesellschaft, Ö., Allgemeinmedizin, Ö. G. F., et al. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-01565-0 · Cited by 18
Special Article: The Normal Hematocrit Cardiac Trial Revisited
Goodkin, D. A. (2009) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2009.00620.x · Cited by 15
“The latter topic has been reviewed recently (32).”
Hirai, T., Nakashima, A., Shiraki, N., Takasugi, N., & Yorioka, N. (2010) · The International Journal of Artificial Organs · doi:10.1177/039139881003300503 · Cited by 15
Wu, S., Yang, C., Xu, N., Wang, L., Liu, Y., Wang, J., & Shen, X. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4553-7 · Cited by 14
“However, a very high dose of peripherally administered EPO is required for tissue protection [12], which consequently increases the incidence of hypertension and hypercoagulation [13, 14].”
BackgroundPathophysiology of Hypertension in Chronic Kidney Disease
Huan, Y., Cohen, D. L., & Townsend, R. R. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00014-7 · Cited by 16
Uchiyama, K., Shibagaki, K., Yanai, A., Kusahana, E., Nakayama, T., Morimoto, K., Washida, N., & Itoh, H. (2021) · Hypertension Research · doi:10.1038/s41440-021-00714-1 · Cited by 13
Li, H., Hu, S.-M., Li, Y., Ciancio, G., Tadros, N. N., Tao, Y., Bai, Y.-J., & Shi, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-5897 · Cited by 13
“Previous study has identified that a high level of EPO is associated with increased risk of hypertension (36).”
Mora‐Gutiérrez, J. M., Ferrer‐Nadal, A., & García-Fernández, N. (2013) · PubMed · doi:10.3265/nefrologia.pre2013.apr.11654 · Cited by 12
THE DIABETIC CKD PATIENT—A MAJOR CARDIOVASCULAR CHALLENGE
van der Meer, I. M., Ruggenenti, P. L., & Remuzzi, G. (2010) · Journal of Renal Care · doi:10.1111/j.1755-6686.2010.00165.x · Cited by 14
Relative Plasma Volume Monitoring for Identifying Volume-Sensitive and -Resistant Hypertension
Agarwal, R. (2010) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2010.00742.x · Cited by 12
“Darbepoietin may have contributed to the difficult to treat hypertension (14).”
BackgroundMomeni, M., Liistro, G., Baele, P., Matta, A., Kahn, D., Dyck, M. V., Kock, M. D., de Kerchove, L., Glineur, D., Thiry, D., et al. (2011) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2011.07.034 · Cited by 11
Risk factors and current state of therapy for anemia after kidney transplantation
Tang, Y., Guo, J., Zhou, J., Wan, Z., Li, J., & Qiu, T. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2023.1170100 · Cited by 11
Agarwal, A. B., & McBride, A. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.04.016 · Cited by 11
Pre-treatment considerations in childhood hypertension due to chronic kidney disease
Olowu, W. A. (2015) · World Journal of Nephrology · doi:10.5527/wjn.v4.i5.500 · Cited by 11
Difficult-to-Treat or Resistant Hypertension: Etiology, Pathophysiology, and Innovative Therapies
Papademetriou, V., Tsioufis, C. P., Gradman, A. H., & Punzi, H. A. (2011) · International Journal of Hypertension · doi:10.4061/2011/438198 · Cited by 16
Clinical parameters before and after the transition to dialysis
Maddux, D. W., Usvyat, L. A., Ketchersid, T. L., Jiao, Y., Blanchard, T. C., Kotanko, P., SANDE, F. M. V. D., Kooman, J. P., & Maddux, F. W. (2017) · Hemodialysis International · doi:10.1111/hdi.12603 · Cited by 10
Ma, Y., Lin, J., Xia, P., Zheng, H., Cheng, X., Ji, P., Wu, W., Hou, L., Wang, L., Zhu, G., et al. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac188 · Cited by 10
Prevalence and Risk Factors of Hypertension in Hemodialysis
Gorsane, I., Mahfoudhi, M., Younsi, F., Helal, I., & Abdallah, T. B. (2015) · Open Journal of Nephrology · doi:10.4236/ojneph.2015.52009 · Cited by 18
“More, ASE used to correct the anemia associated with ESRD are also suspected of causing increases in BP by increased sensitivity to angiotensin II and adrenergic stimuli [27].”
MethodEffect of Erythropoiesis-Stimulating Agents on Blood Pressure in Pre-Dialysis Patients
Suttorp, M., Hoekstra, T., Mittelman, M., Ott, I., Franssen, C. F. M., & Dekker, F. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084848 · Cited by 13
“Previously no difference in BP response between darbepoetin or epoetin in pre-dialysis patients was reported [36,51], and although numbers are small, a stratified analysis according to type of ESA in our data showed the same trend.”
BackgroundResultVecchio, L. D., & Locatelli, F. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.712680 · Cited by 10
“A number of pathophysiological mechanisms have been postulated to explain the rise in blood pressure values observed after ESA administration [39,40].”
BackgroundChen, J., Zhang, Y., Luo, C., Ren, Y., Ye, B., Hu, X., Li, Y., Zhu, B., He, Q., & Shao, L. (2022) · Translational Andrology and Urology · doi:10.21037/tau-22-709 · Cited by 10
“This could be explained by the numerous studies confirming hypertension as a common but frequently overlooked adverse effect of rhEPO therapy (22,23).”
Endothelin-1 and Parameters of Systolic Blood Pressure in Hemodialysis
Singh, A. T., Mothi, S. S., Li, P., Sabbisetti, V. S., Waikar, S. S., & Causland, F. R. M. (2021) · American Journal of Hypertension · doi:10.1093/ajh/hpab104 · Cited by 10
Costa, N. A., Kshirsagar, A. V., Wang, L., Detwiler, R. K., & Brookhart, M. A. (2013) · Transplantation · doi:10.1097/tp.0b013e3182a0f668 · Cited by 9
“ESA also increases systemic arterial blood pressure, most likely from increased blood volume and impaired blood nitric oxide production (62), although only one of the randomized studies of ESA administration showed a significant increased risk of hypertension (63).”
Background
Metadata
- Authors
- Krapf, R., & Hulter, H. N.
- Affiliations
- University of Basel (CH)
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2009-02
- Volume
- 4
- Issue
- 2
- Pages
- 470-480
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2130991130
- Cited by
- 180
- References
- 88
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 7 · 2022: 10 · 2021: 12 · 2020: 7 · 2019: 11 · 2018: 13 · 2017: 10 · 2016: 14 · 2015: 9 · 2014: 13 · 2013: 15 · 2012: 8
- FWCI
- 10.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Keywords
- erythropoietin, erythropoiesis-stimulating agents, hypertension, hemodialysis, continuous ambulatory peritoneal dialysis, chronic kidney disease, blood pressure, hemorheology, erythropoiesis
- MeSH terms
- Anemia, Animals, Arteries, Blood Pressure, Chronic Disease, Erythropoietin, Hematinics, Renal Dialysis, Humans, Hypertension, Kidney Diseases, Peritoneal Dialysis, Continuous Ambulatory, Risk Assessment, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.